A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Key facts
- Who runs it
- Semmelweis University
- Where
- Hungary2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 110 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Extended infusion time of the following beta-lactam: meropenem
- Short-term infusion time of the following beta-lactam: meropenem
- Extended infusion time of the following beta-lactam: piperacillin/tazobactam
- Extended infusion time of the following beta-lactam: cefepime
- Extended infusion time of the following beta-lactam: ceftriaxone
- Short-term infusion time of the following beta-lactam: piperacillin/tazobactam
- Short-term infusion time of the following beta-lactam: cefepime
- Short-term infusion time of the following beta-lactam: ceftriaxone
- Record updated
- 6 November 2026
Who can take part
- Age
- 0 hours to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination
- who are receiving β-lactams including meropenem, piperacillin/tazobactam, cefepime and ceftriaxone
- who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration
- written consent of the parent or guardian is obtained
Who cannot take part
- patients participating in other drug trials
- patients undergoing extracorporeal therapy (continuous kidney replacement therapy [CKRT] or extracorporeal membrane oxygenation [ECMO])
- β-lactam allergy
- patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate [eGFR]<50 mL/min/1.73m2 for meropenem, cefepime, and piperacillin/tazobactam; eGFR<10 mL/min/1.73m2 for ceftriaxone)
- palliative care patients
- patients undergoing plasmapheresis (TPE)
- patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours
- pregnancy
This trial is currently available in Hungary.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.
Read full original descriptionShow less
The main question it aims to answer is:
Is the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.
Participants will:
* be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion. * be examined to make sure their blood drug levels are correct. This will require two blood tests. * be treated according to routine care and have examinations and blood tests performed.
The 2 groups in the trial
- pediatric patients, short-term infusion (P, SI) and neonatal patients, short-term infusion (N, SI)Existing treatment, for comparison
subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age
Treatment: Short-term infusion time of the following beta-lactam: meropenem, Short-term infusion time of the following beta-lactam: piperacillin/tazobactam, Short-term infusion time of the following beta-lactam: cefepime, and Short-term infusion time of the following beta-lactam: ceftriaxone
- pediatric patients, extended infusion (P, EI) and neonatal patients, extended infusion (N, EI)Treatment being tested
subset P: 28 days - 17 years subset N: term or pre-term infants \< 28 days of post-natal age, or PMA\* \< 44 weeks \*postmenstrual age
Treatment: Extended infusion time of the following beta-lactam: meropenem, Extended infusion time of the following beta-lactam: piperacillin/tazobactam, Extended infusion time of the following beta-lactam: cefepime, and Extended infusion time of the following beta-lactam: ceftriaxone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Protocol of a Randomised, Two-arm Superiority Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
- Record updated
- 6 November 2026